We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
-13%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$46B
AUM Growth
-$5.82B
(-11%)
Cap. Flow
+$1.91B
Cap. Flow
% of AUM
4.16%
Top 10 Holdings %
Top 10 Hldgs %
16.37%
Holding
3,033
New
111
Increased
2,420
Reduced
427
Closed
53
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Linde
LIN
|
+$127M |
| 2 |
Cigna
CI
|
+$54M |
| 3 |
CVS Health
CVS
|
+$38.8M |
| 4 |
Marathon Petroleum
MPC
|
+$28.9M |
| 5 |
Diamondback Energy
FANG
|
+$19M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AET
Aetna Inc
AET
|
+$124M |
| 2 |
ESRX
Express Scripts Holding Company
ESRX
|
+$100M |
| 3 |
PX
Praxair Inc
PX
|
+$80.2M |
| 4 |
COL
Rockwell Collins
COL
|
+$43.7M |
| 5 |
ANDV
Andeavor
ANDV
|
+$41M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 16.95% |
| 2 | Financials | 15.85% |
| 3 | Healthcare | 14.41% |
| 4 | Consumer Discretionary | 10.13% |
| 5 | Industrials | 10.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2601
Green Brick Partners
GRBK
$3.08B
| $265K | ﹤0.01% |
36,654
+10,610
| +41% | +$93.5K |
|
2602
Voyager Therapeutics
VYGR
$187M
| $263K | ﹤0.01% |
27,989
+9,086
| +48% | +$117K |
|
|
RUBY
2603
DELISTED
Rubius Therapeutics, Inc
RUBY
| $263K | ﹤0.01% |
16,329
+7,711
| +89% | +$141K |
|
|
PFBI
2604
DELISTED
Premier Financial Bancorp
PFBI
| $262K | ﹤0.01% |
17,599
+2,013
| +13% | +$35.2K |
|
2605
Surgery Partners
SGRY
$1.95B
| $261K | ﹤0.01% |
26,687
+7,900
| +42% | +$106K |
|
2606
Uranium Energy
UEC
$5.34B
| $261K | ﹤0.01% |
208,446
+70,216
| +51% | +$93.3K |
|
|
SCWX
2607
DELISTED
SecureWorks Corp Class A Common Stock
SCWX
| $261K | ﹤0.01% |
15,481
+4,042
| +35% | +$63.4K |
|
|
LJPC
2608
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $260K | ﹤0.01% |
27,594
+9,064
| +49% | +$136K |
|
|
CASI
2609
DELISTED
CASI Pharmaceuticals
CASI
| $259K | ﹤0.01% |
6,440
+2,157
| +50% | +$81.7K |
|
2610
Tilly's
TLYS
$123M
| $259K | ﹤0.01% |
23,824
+10,071
| +73% | +$149K |
|
|
PWOD
2611
DELISTED
Penns Woods Bancorp
PWOD
| $258K | ﹤0.01% |
+9,608
| New | +$268K |
|
2612
Shore Bancshares
SHBI
$808M
| $258K | ﹤0.01% |
17,755
+5,457
| +44% | +$87.7K |
|
|
MNTV
2613
DELISTED
Momentive Global Inc. Common Stock
MNTV
| $258K | ﹤0.01% |
+21,030
| New | +$263K |
|
2614
Fidelity D&D Bancorp
FDBC
$311M
| $257K | ﹤0.01% |
+4,009
| New | +$253K |
|
|
HBMD
2615
DELISTED
Howard Bancorp, Inc. Common Stock
HBMD
| $256K | ﹤0.01% |
17,892
+5,755
| +47% | +$87.7K |
|
|
KDMN
2616
DELISTED
Kadmon Holdings, Inc.
KDMN
| $255K | ﹤0.01% |
122,725
+50,967
| +71% | +$128K |
|
2617
Crinetics Pharmaceuticals
CRNX
$8.92B
| $254K | ﹤0.01% |
+8,475
| New | +$239K |
|
2618
Arq
ARQ
$89.7M
| $254K | ﹤0.01% |
24,072
+7,537
| +46% | +$78.1K |
|
|
ADMS
2619
DELISTED
Adamas Pharmaceuticals
ADMS
| $254K | ﹤0.01% |
29,781
+9,514
| +47% | +$124K |
|
|
TPCO
2620
DELISTED
Tribune Publishing Company Common Stock
TPCO
| $254K | ﹤0.01% |
22,415
+7,155
| +47% | +$104K |
|
2621
C&F Financial
CFFI
$282M
| $253K | ﹤0.01% |
+4,763
| New | +$251K |
|
2622
e.l.f. Beauty
ELF
$5.59B
| $253K | ﹤0.01% |
29,254
+9,651
| +49% | +$109K |
|
|
PRGX
2623
DELISTED
PRGX Global, Inc.
PRGX
| $252K | ﹤0.01% |
26,633
+9,262
| +53% | +$82.4K |
|
2624
Forestar Group
FOR
$1.47B
| $251K | ﹤0.01% |
18,088
+4,539
| +34% | +$75.9K |
|
2625
Teekay Tankers
TNK
$2.68B
| $249K | ﹤0.01% |
33,530
+10,574
| +46% | +$90.7K |
|
Similar funds
VAM
RhumbLine Advisers's Q4 2018 Portfolio in Review
As of Q4 2018, RhumbLine Advisers held 3,033 positions worth $46B, down 11% from $51.8B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
RhumbLine Advisers deployed $1.91B of net new capital in Q4 2018, opening 111 new positions and adding to 2,420 existing holdings. Its largest new stake was Linde: 805,738 shares worth $126M.
By sector, the portfolio is most concentrated in Technology at 17% of assets, down from 18% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Apple, an estimated $30.2M trimmed.
- RhumbLine Advisers's largest Q4 2018 buy was Linde: 805,738 shares worth $126M.
- RhumbLine Advisers added most to Cigna in Q4 2018, an estimated $54M increase.
- RhumbLine Advisers's biggest Q4 2018 reduction was Apple, cutting an estimated $30.2M.
- RhumbLine Advisers fully exited Aetna Inc in Q4 2018, selling an estimated $124M.
- RhumbLine Advisers's ten largest holdings make up 16% of its $46B portfolio in Q4 2018.
- RhumbLine Advisers opened 111 new positions and closed 53 in Q4 2018.
- RhumbLine Advisers's portfolio value fell 11% quarter-over-quarter to $46B.
Based on RhumbLine Advisers's 13F filing for Q4 2018, filed 31 Jan 2019.